Small investment company “Invac” joint venture LLC “Nanolek” and FEDERAL state scientific institution “PNLIP them. M. P. Chumakov wounds” – filed for the registration of the first domestic inactivated polio vaccine (IPV).
The polio vaccine at the Sabin strains will be produced using the technology developed by FSBI “PNLIP them. M. P. Chumakov wounds”. Production of finished dosage forms will be held at the site NANOLEK in the Kirov region. The project involves the construction of additional production capacity.
The planned production capacity will fully meet the additional requirements of Russia in IPV – for a full transition to inactivated polio vaccine as part of NKPP of the Russian Federation and for export to the EEU countries and other overseas markets in cooperation with UNICEF and who.
“It is important to note the relevance of the project not only for Russia, where the annual demand for IPV is estimated at about 8 million doses, but also for export potential. He is, first and foremost, a serious shortage of IPV in the international market related to the program of eradication of polio by who, and systematic transition to the use of inactivated vaccines rather than live. According to expert estimates, the export potential of IPV can be up to 20 million doses annually. Our Institute produces substances on the territory of Russia and has a resolution of the who for supply of vaccines for the needs of UN agencies (“UNICEF”),” – said General Director of “PNLIP them. Chumakov” Aydar Ishmukhametov.